Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astrazeneca Plc ADR
(NQ:
AZN
)
79.33
+1.43 (+1.84%)
Streaming Delayed Price
Updated: 12:14 PM EDT, Jul 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Astrazeneca Plc ADR
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
CALQUENCE® (acalabrutinib) tablet formulation approved in the US across current indications
August 05, 2022
From
AstraZeneca
Via
Business Wire
3 Pharma Stocks' Post-Earnings Price Moves
August 04, 2022
The health care sector is participating in the S&P's nascent rally, but pharmaceuticals AbbVie, Merck and Pfizer are holding up well relative to the market.
Via
MarketBeat
Topics
ETFs
Stocks
Exposures
US Equities
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low metastatic breast cancer
July 25, 2022
From
AstraZeneca
Via
Business Wire
Air Pollution is a Global Heart and Lung Health Concern
July 18, 2022
Palm Beach, FL – July 18, 2022 – FinancialNewsMedia.com News Commentary – Particulate matter or particle pollution is a significant contributor to heart and lung disease. Individuals most affected by...
Via
FinancialNewsMedia
Topics
Climate Change
Emissions
Energy
Exposures
Climate
Fossil Fuels
AstraZeneca Shares Data at EASL and ESMO World GI for IMFINZI® (durvalumab) Combinations in Patients With Liver and Biliary Tract Cancers
July 01, 2022
From
AstraZeneca
Via
Business Wire
IMFINZI® (durvalumab) Plus Chemotherapy Significantly Improved Pathologic Complete Response in AEGEAN Phase III Trial in Resectable Non-Small Cell Lung Cancer
June 30, 2022
From
AstraZeneca Pharmaceuticals
Via
Business Wire
ALXN1840 Shows Rapid and Sustained Improvement in Copper Mobilization From Tissues, Potentially Closing Treatment Gaps for Wilson Disease Community
June 23, 2022
From
Alexion
Via
Business Wire
PROpel Phase III Trial Positive Results of LYNPARZA® (olaparib) Plus Abiraterone in 1st-line Metastatic Castration-resistant Prostate Cancer Published in New England Journal of Medicine Evidence
June 21, 2022
From
AstraZeneca
Via
Business Wire
Eplontersen Met Co-Primary and Secondary Endpoints in Interim Analysis of the NEURO-TTRansform Phase III Trial for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN)
June 21, 2022
From
AstraZeneca
Via
Business Wire
Breakthroughs In Treating Killer Diseases Could Lengthen Life
June 07, 2022
Palm Beach, FL – June 7, 2022 – FinancialNewsMedia.com News Commentary – According to the World Health Organization, top global killers include heart failure, COPD, cancers, Alzheimer’s, neonatal...
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2-Low Metastatic Breast Cancer with HR-Positive and HR-Negative Disease
June 05, 2022
From
AstraZeneca
Via
Business Wire
CALQUENCE Plus Obinutuzumab Demonstrated Sustained Survival Benefit in 1st-line Chronic Lymphocytic Leukemia with 90% of Patients Surviving Five Years in ELEVATE-TN Trial
June 04, 2022
From
AstraZeneca
Via
Business Wire
First Patients Dosed in IRIS Phase III Trial Evaluating Anifrolumab in Lupus Nephritis
May 27, 2022
From
AstraZeneca
Via
Business Wire
AstraZeneca aims to transform cancer care with practice-changing data at ASCO 2022
May 23, 2022
From
AstraZeneca
Via
Business Wire
PT027, a Novel Fixed-Dose Combination of Albuterol and Budesonide, Used as an As-Needed Rescue Medicine, Significantly Reduced the Risk of a Severe Exacerbation Compared to Albuterol by 27% in Patients With Asthma
May 15, 2022
From
AstraZeneca
Via
Business Wire
FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction
May 05, 2022
From
AstraZeneca
Via
Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
May 05, 2022
From
AstraZeneca
Via
Business Wire
ULTOMIRIS® (ravulizumab-cwvz) Met Primary Endpoint in CHAMPION-NMOSD Phase III Trial in Adults with Neuromyelitis Optica Spectrum Disorder
May 05, 2022
From
AstraZeneca
Via
Business Wire
Imfinzi Plus Chemotherapy Granted Priority Review in the US for Patients With Locally Advanced or Metastatic Biliary Tract Cancer Based on TOPAZ-1 Phase III Trial
May 04, 2022
From
AstraZeneca
Via
Business Wire
ULTOMIRIS® (ravulizumab-cwvz) Approved in the US for Adults with Generalized Myasthenia Gravis
April 28, 2022
From
AstraZeneca
Via
Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US for patients with HER2-low metastatic breast cancer
April 27, 2022
From
AstraZeneca
Via
Business Wire
Tremelimumab accepted under Priority Review in the US for patients with unresectable liver cancer in combination with Imfinzi
April 25, 2022
From
AstraZeneca
Via
Business Wire
EVUSHELD™ significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations
April 20, 2022
From
AstraZeneca
Via
Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
April 19, 2022
From
AstraZeneca
Via
Business Wire
ULTOMIRIS® (ravulizumab-cwvz) demonstrated sustained improvements in functional activities and quality of life in adults with generalized myasthenia gravis through 60 weeks
April 06, 2022
From
AstraZeneca
Via
Business Wire
AstraZeneca Announces New Partnership with The National Fish and Wildlife Foundation to Plant One Million Trees
March 24, 2022
From
AstraZeneca
Via
Business Wire
EVUSHELD™ long-acting antibody combination retains neutralizing activity against Omicron variants including BA.2 in new independent studies
March 21, 2022
From
AstraZeneca
Via
Business Wire
LYNPARZA® (olaparib) reduced risk of death by 32% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer
March 16, 2022
From
AstraZeneca
Via
Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Significantly Improved Both Progression-Free and Overall Survival in DESTINY-Breast04 Trial in Patients with HER2-Low Metastatic Breast Cancer
February 21, 2022
From
AstraZeneca
Via
Business Wire
LYNPARZA® (olaparib) plus Abiraterone Reduced Risk of Disease Progression by 34% vs. Standard-of-Care in 1st-Line Metastatic Castration-Resistant Prostate Cancer
February 14, 2022
From
AstraZeneca
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.